Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR. Neoadjuvant lapati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2023-03, Vol.181, p.92-101
Hauptverfasser:	Nuciforo, Paolo, Townend, John, Piccart, Martine J., Fielding, Shona, Gkolfi, Panagiota, El-Abed, Sarra, de Azambuja, Evandro, Werutsky, Gustavo, Bliss, Judith, Moebus, Volker, Colleoni, Marco, Aspitia, Alvaro Moreno, Gomez, Henry, Gombos, Andrea, Coccia-Portugal, Maria A., Tseng, Ling-Ming, Kunz, Georg, Lerzo, Guillermo, Sohn, Joohyuk, Semiglazov, Vladimir, Saura, Cristina, Kroep, Judith, Ferro, Antonella, Cameron, David, Gelber, Richard, Huober, Jens, Di Cosimo, Serena
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - pathology Chemotherapy Confidence intervals Dual anti-HER2 blockade ErbB-2 protein Female HER2-Positive Humans Lapatinib - therapeutic use Long-term survival Neoadjuvant Neoadjuvant Therapy Optimization Pathological complete response Receptor, ErbB-2 Safety Survival Targeted cancer therapy Trastuzumab Trastuzumab - adverse effects Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!